Mandate

Vinge represents Sidec Technologies in the issue of new shares

May 09, 2007

Vinge is representing Sidec Technologies, in conjunction with the investments by Industrifonden, Investor and Earlybird of Germany in the company. A capital infusion of SEK 68.5 million means that Sidec can implement its planned efforts on the European and American markets. The company, which was established in 2000, is a spin-off from research at the Karolinska Institute, and is engaged in technology developed for studies of protein.
 
Partner Johan Winnerbald and associate Anna Berntsson represent Sidec Technologies AB.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026